Boris Turk Selected Research

Cysteine (L-Cysteine)

1/2022	Evaluation of novel cathepsin-X inhibitors in vitro and in vivo and their ability to improve cathepsin-B-directed antitumor therapy.
12/2021	Cystatin C Deficiency Increases LPS-Induced Sepsis and NLRP3 Inflammasome Activation in Mice.
2/2021	Altered Expression of Peroxiredoxins in Mouse Model of Progressive Myoclonus Epilepsy upon LPS-Induced Neuroinflammation.
12/2020	Intracellular cathepsin C levels determine sensitivity of cells to leucyl-leucine methyl ester-triggered apoptosis.
1/2020	Cysteine cathepsins as therapeutic targets in inflammatory diseases.
11/2019	Upregulation of Mitochondrial Redox Sensitive Proteins in LPS-Treated Stefin B-Deficient Macrophages.
11/2019	Stefin A-functionalized liposomes as a system for cathepsins S and L-targeted drug delivery.
2/2018	Selective imaging of cathepsin L in breast cancer by fluorescent activity-based probes.
10/2017	The Future of Cysteine Cathepsins in Disease Management.
9/2017	Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Boris Turk Research Topics

Disease

36	Neoplasms (Cancer) 01/2022 - 01/2002
13	Inflammation (Inflammations) 01/2020 - 08/2006
6	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2015
6	Neoplasm Metastasis (Metastasis) 09/2019 - 05/2004
6	Rheumatoid Arthritis 01/2019 - 01/2007
6	Osteoporosis 09/2015 - 02/2004
5	Unverricht-Lundborg Syndrome (Disease, Unverricht) 02/2021 - 03/2010
4	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021 - 12/2016
4	Sepsis (Septicemia) 12/2021 - 11/2014
4	Carcinogenesis 02/2018 - 05/2004
3	Infections 01/2020 - 01/2006
3	Osteoarthritis 03/2015 - 01/2007
2	Animal Disease Models 01/2022 - 02/2009
2	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 08/2014
2	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 06/2021 - 12/2016
2	Immune System Diseases (Immune Disorders) 01/2020 - 01/2007
2	Arthritis (Polyarthritis) 01/2020 - 02/2004
2	Disease Progression 11/2019 - 06/2014
2	Melanoma (Melanoma, Malignant) 12/2018 - 05/2015
2	Bone Resorption 10/2017 - 08/2014
2	Pathologic Processes 03/2016 - 07/2015
2	Chagas Disease (American Trypanosomiasis) 04/2008 - 01/2006
1	Seizures (Absence Seizure) 02/2021
1	Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy) 02/2021
1	Neuroinflammatory Diseases 02/2021
1	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2020
1	Bacterial Infections (Bacterial Infection) 01/2020
1	Periodontitis 01/2020
1	Salmonella Infections (Salmonellosis) 01/2020
1	Acute-Phase Reaction 12/2019
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 11/2019
1	Necrosis 01/2019
1	Lung Diseases (Lung Disease) 01/2017
1	Fibrosarcoma 08/2015
1	Pancreatic Neoplasms (Pancreatic Cancer) 08/2015

Drug/Important Bio-Agent (IBA)

39	CathepsinsIBA 01/2022 - 01/2002
25	Cysteine (L-Cysteine)FDA Link 01/2022 - 05/2004
14	Proteins (Proteins, Gene)FDA Link 11/2021 - 05/2005
13	Peptide Hydrolases (Proteases)FDA Link 10/2020 - 02/2004
9	Cathepsin BIBA 01/2022 - 05/2005
9	Pharmaceutical PreparationsIBA 12/2020 - 02/2004
6	Cystatin BIBA 02/2021 - 03/2010
5	EnzymesIBA 01/2022 - 04/2005
5	cathepsin SIBA 08/2015 - 02/2011
4	Cathepsin KIBA 10/2017 - 01/2007
3	Protease Inhibitors (Protease Inhibitor)IBA 01/2022 - 09/2017
3	ProteomeIBA 01/2020 - 02/2018
3	Biological ProductsIBA 01/2020 - 01/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2019 - 11/2014
3	CytokinesIBA 11/2014 - 09/2009
2	Cystatin CIBA 12/2021 - 09/2017
2	LipopolysaccharidesIBA 02/2021 - 11/2019
2	Cathepsin CIBA 12/2020 - 04/2014
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020 - 08/2015
2	Cysteine Proteases (Cysteine Protease)IBA 01/2020 - 09/2014
2	Fluorescent Dyes (Fluorescent Probes)IBA 09/2019 - 02/2018
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 09/2009
2	Cathepsin LIBA 02/2018 - 01/2012
2	Biomarkers (Surrogate Marker)IBA 01/2015 - 06/2014
2	CaspasesIBA 01/2012 - 01/2006
2	polyalanineIBA 08/2009 - 06/2009
1	TriazolesIBA 01/2022
1	DioxinsIBA 01/2022
1	InflammasomesIBA 12/2021
1	Cysteine Proteinase InhibitorsIBA 12/2021
1	Cadherins (E-Cadherin)IBA 11/2021
1	Cathepsin DIBA 06/2021
1	PeroxiredoxinsIBA 02/2021
1	Thioredoxin-Disulfide ReductaseIBA 02/2021
1	ThioredoxinsIBA 02/2021
1	leucyl-leucine-methyl esterIBA 12/2020
1	Detergents (Detergent)IBA 12/2020
1	IsotopesIBA 01/2020
1	Gingipain Cysteine EndopeptidasesIBA 01/2020
1	Amino Acids FDA Link 01/2020
1	MetalsIBA 01/2020
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2020
1	NucleotidesIBA 11/2019
1	Leucine (L-Leucine)FDA Link 11/2019
1	Liposomes (Liposome)IBA 11/2019
1	Cystatin AIBA 11/2019
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2019
1	lastar AIBA 01/2019
1	tempolIBA 01/2019
1	Tocopherols (Tocopherol)IBA 01/2019
1	Vitamin K 3 (Menadione)FDA Link 01/2019
1	Superoxide DismutaseIBA 01/2019
1	ChloridesIBA 01/2019
1	StaurosporineIBA 01/2019
1	hydroxide ionIBA 12/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2018
1	Aluminum Hydroxide (Algeldrate)FDA Link 12/2018
1	Oncogene Proteins (Oncogene Protein)IBA 09/2017
1	14-3-3 Proteins (14-3-3 Protein)IBA 09/2017
1	Designed Ankyrin Repeat ProteinsIBA 01/2017
1	EndopeptidasesIBA 08/2015
1	nitroxolineIBA 08/2015
1	CollagenIBA 08/2015

Therapy/Procedure

7	Therapeutics 01/2022 - 01/2007
2	Precision Medicine 01/2017 - 01/2015